Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Number of Injections, ASP, Volume by Therapy Type, Route of Administration & End-User The global autoinjectors market will witness a robust CAGR of 17.9%, valued at $2.88 Billion in 2021, expected to appreciate and reach $12.67 Billion by 2030, confirms Strategic Market Research. The industry is seeing an increased growth due to expanded utilization of adrenaline, food allergens, EpiPen autoinjector, autoinjector pen, autoinjector syringe and anaphylaxis. In addition, health care providers utilize autoinjectors mainly because of their benefits, such as accurate drug dosage, minimizing phobias related to the needle, etc. Market Dynamics: - Driver: (Increase in targeted therapies, regulatory approvals, and anaphylaxis are considered to be the main drivers for industry growth) Increased occurrence of anaphylaxis is accounted for the growth of autoinjectors market size. Anaphylaxis is a condition wherein patients suffer from a dangerous allergic reaction that is life-threatening caused due to drugs, latex, food, and Hymenoptera stings. An adrenaline autoinjector is used to treat anaphylaxis. Anaphylaxis is so common that we find causality in 1 in every 1000 cases, as reported by NICE studies. European Journal of Allergy and Clinical Immunology 2019 studies reported that globally there is a significant variation with respective children who are affected by anaphylaxis. Of the 1,00,000 population every year, at least 1 to 761 are victims of anaphylaxis, while 1 to 77 is reported to have anaphylaxis caused related to food. EpiPen autoinjector or Epinephrine is the first-ever invented treatment for anaphylaxis. Most of the major pharmaceutical industries are trying to develop technologically fast-paced epinephrine autoinjectors (EAIs) for treating anaphylaxis. Portable devices, innovative designs, one device which can accommodate two auto-injectable doses, EpiPen autoinjector for infants which consists of 0.1mg dose, EpiPen autoinjector for adults which consists of 0.5-0.75mg dose, increased shelf life, autoinjectors which have more excellent stability towards temperature, casing which is resistant to weather and impact are few of the technological developments that are seen recently. The mentioned technologically advanced features could be accounted for the growth in usage of autoinjectors. Restraints: (High costs and availability of substitute modes) Availability of a vast range of other modes of drug delivery and higher costs associated with autoinjectors are the restraints faced by Global Autoinjector Market. In addition, difficulty in the availability of autoinjectors is also one of the hindrances to the autoinjector market size. Opportunities: (Reduced physical contact and consultation) Development in technology and pharmaceutical companies and an increase in investment in R&D can be accounted for the path of the future opportunities in this segment and hence it is driving the overall autoinjector market growth. Global Autoinjectors Market Analysis of different Segmentations: Therapy, Type, Route of Administration, and End User are types based on which industry is segmented. By Therapy Anaphylaxis Diabetes Multiple Sclerosis Rheumatoid Arthritis Other Therapies By Type Reusable Autoinjectors Disposable Autoinjectors By Route of Administration Intramuscular Subcutaneous By End-User Hospitals & Clinics Home Care Settings Ambulatory Care Settings By Region Europe Germany UK France Italy Spain North America US Canada Asia-Pacific China Japan India Rest of Asia-Pacific Latin America The Middle East and Africa Based on the type of therapy used, Rheumatoid Arthritis contributed to the largest market share. A rise in the number of people affected by arthritis is the driver for the significant market share of this segment. Based on the type of autoinjectors, disposable autoinjectors contributed to the largest market share. Drivers that constitute this segment's market share are their ease of use and having a build-in glass syringe, which helps eliminate the loading of glass syringe manually, making it easier for patients who have decreased dexterity or visual impairments. Based on route of administration, subcutaneous contributed to the largest market share in Global Autoinjectors Market. Drivers that constitute this segment's market share are an increase in the number of chronic diseases and their treatment approvals by the regulatory bodies. Based on the end-user, the home care setting contributed to the largest market share in Market. Drivers that constitute this segment's market share are required for a cost-effective drug delivery system and the rise in the geriatric population. Based on the region, North America contributed the largest market share in Market, followed by the Asia Pacific. Currently, North America has a market share of approximately 41%. It is estimated to have a 19-22% CAGR during the forecasted period. Drivers that constitute this segment's market share are an increase in chronic diseases and autoimmune diseases. Global Autoinjectors Market Competitive Landscape Analysis Many major pharmaceutical giants are working on the development of the industry GlaxoSmithKline plc Merck KGaA Johnson & Johnson Dickinson and Company AbbVie Inc Eli Lilly and Company Antares Pharma Amgen Ypsomed Mylan Teva Pharmaceutical Autoinjectors Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 2.88 billion The revenue forecast in 2030 USD 12.67 billion Growth rate CAGR of approximately 17.9% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Therapy, By Type, By Route of Administration, By End-User, By Region By Therapy Anaphylaxis, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Other Therapies By Type Reusable Autoinjectors, Disposable Autoinjectors By Route of Administration Intramuscular, Subcutaneous By End-User Hospitals & Clinics, Home Care Settings, Ambulatory Care Settings By Region Europe, North America, Asia-Pacific, Latin America Country Scope United States of America, Mexico, United Arab Emirates, United Kingdom, Germany, France, Canada, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, South Africa Company Usability Profiles GlaxoSmithKline plc, Merck KGaA, Johnson & Johnson, Dickinson and Company, AbbVie Inc, Eli Lilly and Company, Antares Pharma, Amgen, Ypsomed, Mylan, Teva Pharmaceutical Recent Developments In 2021 a strategic partnership between Eversana and Experic aiming at commercialization, development, lunch planning, and optimizing manufacturing was announced. The main objective of this strategic partnership was to eliminate the inabilities present in the traditional industry. With the help of this partnership, both the companies can serve more than 600 pharmaceutical companies and new start-ups. In August 2020, Saudi Arabia's supply and regulatory approval body XYOSTED enabled an agreement between Antares Pharma and Lunatus Global. According to the agreement, Antares Pharma will look after packaging manufacturing while Lunatus Global looks after getting approvals, promotion, and distribution. Frequently Asked Question About This Report What are the major drivers for the market? An increase in targeted therapies, regulatory approvals, and anaphylaxis are the main drivers for auto injector’s market growth. Who are the major key players? GlaxoSmithKline plc, Merck KGaA, Johnson & Johnson, Dickinson and Company, AbbVie Inc, Eli Lilly and Company, Antares Pharma, Amgen, Ypsomed, Mylan, Teva Pharmaceutical. Based on end-user, which segment has a significant market share? Based on the end-user home care setting, subcutaneous contributed to the largest market share in Global Autoinjectors Market. Drivers that constitute this segments market share are required for a cost-effective drug delivery system and the rise in the geriatric population. Based on region, which segment has a significant market share? Based on the region, North America contributed the largest market share in Global Autoinjectors Market, followed by the Asia Pacific. Currently, North America has a market share of approximately 41%. It is estimated to have a 19-22% CAGR during the forecasted period. Drivers that constitute this segments market share are an increase in chronic diseases and autoimmune diseases. How big is the autoinjectors market size? The global autoinjectors market size was $54.23 billion in 2021 and is predicted to reach $238.7 billion by 2030, with a CAGR of 17.9%. What is the autoinjectors market growth? The global autoinjectors market is expected to grow at a compound annual growth rate (CAGR) of 17.9 % from 2021 to 2030 to reach USD $ 238.7 billion by 2030. Sources https://seekingalpha.com/article/4421394-antares-pharma-uncertainty-limits-share-price-appreciation https://www.researchgate.net/publication/330682371_The_global_incidence_and_prevalence_of_anaphylaxis_in_children_in_the_general_population_A_systematic_review? https://www.eversana.com/2020/12/17/eversana-and-experic-announce-strategic-partnership-to-optimize-end-to-end-contract-manufacturing-and-commercialization-services-for-life-sciences-industry/ https://www.streetinsider.com/Corporate%2BNews/Antares%2BPharma%2B%28ATRS%29%2C%2BLunatus%2BEnter%2BInto%2Ban%2BExclusive%2BDistribution%2BAgreement%2Bfor%2BXYOSTED%C2%AE%2Bin%2BSaudi%2BArabia%2Band%2Bthe%2BUnited%2BArab%2BEmirates/17184562.html 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Autoinjectors Market 4.2.1 Global market, 2021 – 2030 (USD Million) 4.3 Regional Analysis 4.3.1 Global market, by region, 2021 - 2030 (USD Million) 4.4 By Therapy Analysis 4.4.1 Global market, By Therapy, 2021 - 2030 (USD Million) 4.5 By End-User Business Analysis 4.5.1 Global market, By End-User, 2021 - 2030 (USD Million) 4.6 Type Analysis 4.6.1 Global market, By Type, 2021 - 2030 (USD Million) 4.6 Route of Administration Analysis 4.6.1 Global market, By Route of Administration, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 market PEST analysis 4.9.2 market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Route of Administration Analysis 5.11.1. Trends in Route of Administration (2014-2021) 5.11.2. Trends in Route of Administration (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Therapy Therapy 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Therapy Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Anaphylaxis 7.3.1. Anaphylaxis market, 2021 - 2030 (USD Million) 7.4. Diabetes 7.4.1. Diabetes market, 2021 - 2030 (USD Million) 7.5. Multiple Sclerosis 7.5.1. Multiple Sclerosis market, 2021 - 2030 (USD Million) 7.6. Rheumatoid Arthritis 7.6.1. Rheumatoid Arthritis market, 2021 - 2030 (USD Million) 7.7. Other Therapies 7.7.1. Other Therapies market, 2021 - 2030 (USD Million) 8. Global Market: By End-User Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Hospitals & Clinics 8.3.1. Hospitals & Clinics market, 2021 - 2030 (USD Million) 8.4. Home Care Settings 8.4.1. Home Care Settings market, 2021 - 2030 (USD Million) 8.5. Ambulatory Care Settings 8.5.1. Ambulatory Care Settings market, 2021 - 2030 (USD Million) 9. Global Market: By Type Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Reusable 9.3.1. Reusable market, 2021 - 2030 (USD Million) 9.4. Disposable 9.4.1. Disposable market, 2021 - 2030 (USD Million) 10. Global Market: By Route of Administration Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Intramuscular 10.3.1. Intramuscular market, 2021 - 2030 (USD Million) 10.4. Subcutaneous 10.4.1. Subcutaneous market, 2021 - 2030 (USD Million) 11. Global Market: Regional Outlook 11.1 North America 11.1.1. North America market, by By Therapy, 2021 - 2030 (USD Million) 11.1.2. North America market, by By End-User, 2021 - 2030 (USD Million) 11.1.3. North America market, by Route of Administration, 2021 - 2030 (USD Million) 11.1.4. North America market, by Country, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. market, by By Therapy, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. market, by By End-User, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. market, by Route of Administration, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada market, by By Therapy, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada market, by By End-User, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada market, by Route of Administration, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe market, by By Therapy, 2021 - 2030 (USD Million) 11.2.2. Europe market, by By End-User, 2021 - 2030 (USD Million) 11.2.3. Europe market, by Route of Administration, 2021 - 2030 (USD Million) 11.2.4. Europe market, by country, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. market, by By Therapy, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. market, by By End-User, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. market, by Route of Administration, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany market, by By Therapy, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany market, by By End-User, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany market, by Route of Administration, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France market, by By Therapy, 2021 - 2030 (USD Million) 11.2.4.3.2. France market, by By End-User, 2021 - 2030 (USD Million) 11.2.4.3.3. France market, by Route of Administration, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe market, by By Therapy, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe market, by By End-User, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe market, by Route of Administration, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific market, by By Therapy, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific market, by By End-User, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific market, by Route of Administration, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific market, by country, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China market, by By Therapy, 2021 - 2030 (USD Million) 11.3.4.1.2. China market, by By End-User, 2021 - 2030 (USD Million) 11.3.4.1.3. China market, by Route of Administration, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India market, by By Therapy, 2021 - 2030 (USD Million) 11.3.4.2.2. India market, by By End-User, 2021 - 2030 (USD Million) 11.3.4.2.3. India market, by Route of Administration, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan market, by By Therapy, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan market, by By End-User, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan market, by Route of Administration, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea market, by By Therapy, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea market, by By End-User, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea market, by Route of Administration, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC market, by By Therapy, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC market, by By End-User, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC market, by Route of Administration, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America market, by By Therapy, 2021 - 2030 (USD Million) 11.4.2. Latin America market, by By End-User, 2021 - 2030 (USD Million) 11.4.3. Latin America market, by Route of Administration, 2021 - 2030 (USD Million) 11.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil market, by By Therapy, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil market, by By End-User, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil market, by Route of Administration, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico market, by By Therapy, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico market, by By End-User, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico market, by Route of Administration, 2021 - 2030 (USD Million) 11.4.4.3. Rest of the Latin America 11.4.4.3.1. Rest of the Latin America market, by By Therapy, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America market, by By End-User, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America market, by Route of Administration, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA market, by By Therapy, 2021 - 2030 (USD Million) 11.5.2. MEA market, by By End-User, 2021 - 2030 (USD Million) 11.5.3. MEA market, by Route of Administration, 2021 - 2030 (USD Million) 11.5.4. MEA market, by Region, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 GlaxoSmithKline plc 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Therapy Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Merck KGaA 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Therapy Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. Johnson & Johnson 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Therapy Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. Dickinson and Company 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Therapy Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. AbbVie Inc 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Therapy Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. Eli Lilly and Company 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Therapy Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. Antares Pharma 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Therapy Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. Amgen 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Therapy Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. Ypsomed 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Therapy Portfolio Analysis 12.9.4. Business Strategy & Recent Development 12.10. Mylan 12.10.1. Company overview 12.10.2. Financial performance 12.10.3. Therapy Portfolio Analysis 12.10.4. Business Strategy & Recent Development 12.11. Teva Pharmaceutical 12.11.1. Company overview 12.11.2. Financial performance 12.11.3. Therapy Portfolio Analysis 12.11.4. Business Strategy & Recent Development List of Tables (55 Tables) TABLE 1. MARKET, By Therapy, 2021-2030 (USD Million) TABLE 2. MARKET FOR Anaphylaxis, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Multiple Sclerosis, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Rheumatoid Arthritis, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Other Therapies, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET, By End-User, 2021-2030 (USD Million) TABLE 8. MARKET FOR Hospitals & Clinics, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Home Care Settings, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Ambulatory Care Settings, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Intramuscular, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Subcutaneous, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET, BY Type, 2021-2030 (USD Million) TABLE 15. MARKET FOR Reusable , BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Disposable , BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 18. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA MARKET, By Therapy, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA MARKET, By End-User, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 22. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 23. EUROPE MARKET, By Therapy, 2021-2030 (USD Million) TABLE 24. EUROPE MARKET, By End-User, 2021-2030 (USD Million) TABLE 25. EUROPE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 26. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC MARKET, By Therapy, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC MARKET, By End-User, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 30. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 31. LAMEA MARKET, By Therapy, 2021-2030 (USD Million) TABLE 32. LAMEA MARKET, By Type, 2021-2030 (USD Million) TABLE 33. LAMEA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 34. GlaxoSmithKline plc: COMPANY SNAPSHOT TABLE 35. GlaxoSmithKline plc: OPERATING SEGMENTS TABLE 36. Merck KGaA: COMPANY SNAPSHOT TABLE 37. Merck KGaA: OPERATING SEGMENTS TABLE 38. Johnson & Johnson: COMPANY SNAPSHOT TABLE 39. Johnson & Johnson: OPERATING SEGMENTS TABLE 40. Dickinson and Company: COMPANY SNAPSHOT TABLE 41. Dickinson and Company: OPERATING SEGMENTS TABLE 42. AbbVie Inc: COMPANY SNAPSHOT TABLE 43. AbbVie Inc: OPERATING SEGMENTS TABLE 44. Eli Lilly and Company: COMPANY SNAPSHOT TABLE 45. Eli Lilly and Company: OPERATING SEGMENTS TABLE 46. Antares Pharma: COMPANY SNAPSHOT TABLE 47. Antares Pharma: OPERATING SEGMENTS TABLE 48. Amgen: COMPANY SNAPSHOT TABLE 49. Amgen: OPERATING SEGMENTS TABLE 50. Ypsomed: COMPANY SNAPSHOT TABLE 51. Ypsomed: OPERATING SEGMENTS TABLE 52. Mylan: COMPANY SNAPSHOT TABLE 53. Mylan: OPERATING SEGMENTS TABLE 54. Teva Pharmaceutical: COMPANY SNAPSHOT TABLE 55. Teva Pharmaceutical: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Therapy-Based Estimation Figure 6 Top 11 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for , By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for , By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By End-User, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Route of Administration, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Therapy, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Type, 2019 vs. 2025 (USD Million) Figure 15 Geographical Snapshot of the Market Figure 16 Rheumatoid Arthritis to Witness Higher CAGR in Market for Therapy Segment during Forecast Period. Figure 17 Subcutaneous to Witness Higher CAGR in Market for Route of Administration Segment during Forecast Period. Figure 18 home care setting to Witness Higher CAGR in Market for End-User Segment during Forecast Period. Figure 19 Disposable to Witness Higher CAGR in Market for Type Segment during Forecast Period. Figure 20 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 21 Market: Drivers, Restraints, Opportunities, and Challenges Figure 22 North America: Market Snapshot Figure 23 Asia Pacific: Market Snapshot Figure 24 Vendor Dive: Evaluation Overview